



Novel Biomarkers for Acute and Chronic Heart Failure

Guest Editors:

Dr. Josep Comín-Colet

Dr. Cristina Enjuanes-Grau

Hospital Universitari de Bellvitge,
Barcelona, Spain

Deadline for manuscript
submissions:

closed (10 July 2023)

Message from the Guest Editors

Dear Colleagues,

Heart failure is acknowledged as a major and growing public health problem. It is currently a devastating syndrome with a very negative impact on mortality, morbidity, and health-related quality of life. Heart failure is also considered an international priority in healthcare due to its growing prevalence and to the rising medical resource use and expenditure.

The use of biomarkers in the management of patients with heart failure has increased over the past few years. Biomarkers contribute to making reliable tools for a systematic and optimized strategy in heart failure diagnosis and treatment. Recent advances in research have settled the basis for biomarker testing and diagnostic evaluation in heart failure; however, there are still many gaps of knowledge regarding the use of biomarkers for patient-centered integrated early diagnosis and risk stratification.

This Special Issue will provide novel findings and innovations in the field of biomarkers, to ensure more efficiency for heart failure condition through multidisciplinary and integrated management approach.

Dr. Josep Comín-Colet

Dr. Cristina Enjuanes-Grau

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)